UChicago Leukemia Program

Treatment Algorithm series: Acute Myeloid Leukemia (AML) w/ @Anand_88_Patel ✅ Importance of molecular testing ✅ Rx for fit/unfit pts ✅ R/R disease Full discussion: - Oncbrothers.com/algo-AML-2025 - Also on the “Oncology Brothers” podcast #HemeTwitter #OncTwitter @OncUpdates

congrats to Dr Yates and @Anand_88_Patel!

new article on palliative care research in AYAs featuring @AyaOncologist as senior author! pubmed.ncbi.nlm.nih.gov/40660632/

Very excited to share our paper investigating the evolution of therapy-related CH in myeloma pts treated w/ or w/o LEN. Can we predict the risk for second blood cancer in myeloma pts? Grateful for the collaboration with @UCCancerCenter myeloma program. nature.com/articles/s4137…

a huge congratulations to @Anand_88_Patel for being selected for a @theNCI Early Career Investigator Award! @UCCancerCenter @UChicagoHemOnc reporter.nih.gov/search/5QB1uxC…

A new review led by @LeivaOrly and featuring @UChicagoLeuk faculty @Anand_88_Patel @myeloidmalig is focused on pulmonary HTN and HF in patients with MPNs! jacc.org/doi/10.1016/j.…

the ELN has posted their 2025 CML guidelines including Dr Richard Larson as co-author! nature.com/articles/s4137…

We were thrilled to welcome our incoming first-year fellows to the program earlier this week. Orientation is officially complete ✅. Here’s to a year of growth, learning, and meaningful impact—let the adventure begin! @UChicagoHemOnc @UCCancerCenter @HemOncFellows

check out this upcoming @HealthTree virtual lecture by @Anand_88_Patel on primary vs secondary myelofibrosis! healthtree.org/myelofibrosis/…

UChicago Medicine is searching for a Director of Supportive Oncology. The appointee will be responsible for the development, expansion, management, and alignment of services reflected in a patient’s cancer journey. If interested, please apply! apply.interfolio.com/163026

Two new publications featuring @mariamtn89 as co-author from the ASTCT! pubmed.ncbi.nlm.nih.gov/40614969/ pubmed.ncbi.nlm.nih.gov/40609744/

Congrats to co-editor/author @Anand_88_Patel and chapter author @michaelwd_hem on the release of the @ASH_hematology Self Assessment Program 9th Edition! ashpublications.org/books/book/10/…

An excellent thread on a high-impact study in B-ALL featuring @DrWendyStock as co-author!

Check out this editorial by @RoloffGreg (with a very catchy title!) in @Haematologica on development of myeloid disorders after CD19 CART cell therapy! haematologica.org/article/view/1…

check out this new manuscript featuring @DrWendyStock as co-author that looks at cytarabine pharmacogenomics in children/AYAs with AML pubmed.ncbi.nlm.nih.gov/40549387/

new publication featuring @myeloidmalig as a co-author focused on efficacy of decitabine-cedazuridine in patients with CMML! pubmed.ncbi.nlm.nih.gov/40524338/

CONGRESS | #EHA2025 | POSTER Wendy Stock @DrWendyStock @UChicago shares outcomes from a pooled analysis of three studies in pts with B-ALL receiving inotuzumab ozogamicin (InO) stratified by BMI. Efficacy and safety outcomes were broadly consistent across BMI groups for pts with…

Check out long-term CALGB10403 data presented by @DrWendyStock!

new research led by @rafmadero @Anand_88_Patel and featuring several @UChicagoLeuk program members that reports using of additional venetoclax-containing regimens in pts prev treated w HMA+VEN dx.doi.org/10.1002/jha2.7…

congrats to @DrWendyStock & @myeloidmalig who are co-authors on the @JCO_ASCO publication focusing on the BEAT AML cohort of patients treated with Aza + Ven + Revumenib! ascopubs.org/doi/10.1200/JC…